Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo

Sign up to receive the latest information about SANCUSO® (granisetron transdermal system)


Are you prescribing SANCUSO?

Kyowa Kirin, Inc. respects your interest in keeping your personal and professional information private. We will not sell or rent your information to any third parties or outside mailing lists.

By clicking “Submit” and providing your name, email address, or other personal information, you agree that Kyowa Kirin and others working on behalf of Kyowa Kirin may send you content updates and educational materials about chemotherapy-induced nausea and vomiting (CINV) and SANCUSO, use the information that you have submitted to develop or improve products and services, and contact you in the future about educational programs, health-related topics, and advancements in the treatment of CINV. Kyowa Kirin respects the privacy of visitors to its websites, and we recognize your need for protection and management of personally identifiable information you share with us (any information by which you can be identified, including, but not limited to, name, address, email address, and telephone number). Click here to read the Kyowa Kirin Privacy Policy.

Indication and Important Safety Information


Sancuso® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.


Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.


Adverse Reactions

The most common adverse reaction (≥ 3%) is constipation.

You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals Inc. at 1-800-Sancuso or FDA at 1-800-FDA-1088 or

See full Prescribing Information for SANCUSO.